| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1100822107 |
| P356 | DOI | 10.1186/S12934-018-0868-0 |
| P932 | PMC publication ID | 5798182 |
| P698 | PubMed publication ID | 29402276 |
| P50 | author | Gerhard Schembecker | Q83401379 |
| David Wetzel | Q87174417 | ||
| Catherine S Palmer | Q58121934 | ||
| P2093 | author name string | James G Beeson | |
| Betty Kouskousis | |||
| Jo-Anne Chan | |||
| Andreas Barbian | |||
| Manfred Suckow | |||
| Volker Jenzelewski | |||
| Juliane Merz | |||
| Michael Piontek | |||
| Andreas Kranz | |||
| Michael Weniger | |||
| Theresa Rolf | |||
| Joachim Leitsch | |||
| P2860 | cites work | An expression system matures: a highly efficient and cost-effective process for phytase production by recombinant strains of Hansenula polymorpha | Q74661119 |
| Glycoprotein E1 of hog cholera virus expressed in insect cells protects swine from hog cholera | Q24656017 | ||
| Role of cultivation media in the development of yeast strains for large scale industrial use | Q24813106 | ||
| Antibiotic-free selection in biotherapeutics: now and forever | Q27028105 | ||
| Current Status of Veterinary Vaccines | Q27480923 | ||
| Live attenuated pseudorabies virus expressing envelope glycoprotein E1 of hog cholera virus protects swine against both pseudorabies and hog cholera | Q27486212 | ||
| Crystal structure of glycoprotein E2 from bovine viral diarrhea virus | Q27677276 | ||
| Immune responses to duck hepatitis B virus infection | Q28138622 | ||
| A simplification of the protein assay method of Lowry et al. which is more generally applicable | Q29615220 | ||
| Epidemiology of dengue: past, present and future prospects | Q30664159 | ||
| Peptide mapping of neutralizing and nonneutralizing epitopes of duck hepatitis B virus pre-S polypeptide | Q33260631 | ||
| Methylotrophic yeasts near Ogataea (Hansenula) polymorpha: a proposal of Ogataea angusta comb. nov. and Candida parapolymorpha sp. nov. | Q33584051 | ||
| St, a truncated envelope protein derived from the S protein of duck hepatitis B virus, acts as a chaperone for the folding of the large envelope protein. | Q33755001 | ||
| Subviral particle as vaccine and vaccine platform | Q33812653 | ||
| Classical swine fever: the global situation. | Q33900774 | ||
| CBB staining protocol with higher sensitivity and mass spectrometric compatibility | Q34099297 | ||
| Prolonged incubation in calcium chloride improves the competence of Escherichia coli cells | Q34192132 | ||
| Virus of Pekin ducks with structural and biological relatedness to human hepatitis B virus | Q34288062 | ||
| Bacterial superglue enables easy development of efficient virus-like particle based vaccines | Q34523734 | ||
| Virus-like particle production with yeast: ultrastructural and immunocytochemical insights into Pichia pastoris producing high levels of the hepatitis B surface antigen | Q35123908 | ||
| Applications of viral nanoparticles in medicine. | Q35501007 | ||
| Susceptibility to duck hepatitis B virus infection is associated with the presence of cell surface receptor sites that efficiently bind viral particles | Q35844533 | ||
| Current strategies for the use of affinity tags and tag removal for the purification of recombinant proteins | Q36374029 | ||
| Virus-like particles: passport to immune recognition | Q36602264 | ||
| The control of bovine viral diarrhoea virus in Europe: today and in the future | Q36760223 | ||
| Vaccines and animal welfare. | Q36882927 | ||
| A global perspective on the epidemiology of West Nile virus | Q36888981 | ||
| Simple high-cell density fed-batch technique for high-level recombinant protein production with Pichia pastoris: Application to intracellular production of Hepatitis B surface antigen | Q37107055 | ||
| Engineering virus-like particles as vaccine platforms | Q37172342 | ||
| A targeted mutation within the feline leukemia virus (FeLV) envelope protein immunosuppressive domain to improve a canarypox virus-vectored FeLV vaccine. | Q37547454 | ||
| Virus-like particles in vaccine development. | Q37798008 | ||
| Virus-like particles: potential veterinary vaccine immunogens | Q37958442 | ||
| Virus-like particles: the new frontier of vaccines for animal viral infections. | Q38019283 | ||
| Reengineering viruses and virus-like particles through chemical functionalization strategies | Q38087024 | ||
| Virus-like particles: the future of microbial factories and cell-free systems as platforms for vaccine development | Q38088523 | ||
| Use of baculovirus expression system for generation of virus-like particles: successes and challenges | Q38112493 | ||
| Virus-like particle-based human vaccines: quality assessment based on structural and functional properties | Q38152530 | ||
| The challenges of classical swine fever control: modified live and E2 subunit vaccines | Q38161261 | ||
| Protein expression in Pichia pastoris: recent achievements and perspectives for heterologous protein production. | Q38205379 | ||
| Diseases associated with spontaneous feline leukemia virus (FeLV) infection in cats | Q38286490 | ||
| Replicon Particle Expressing the E2 Glycoprotein of Bovine Viral Diarrhea Virus Immunization and Evaluation of Antibody Response | Q38689402 | ||
| Effects of glycosylation on antigenicity and immunogenicity of classical swine fever virus envelope proteins. | Q39463827 | ||
| Hepadnavirus envelope topology: insertion of a loop region in the membrane and role of S in L protein translocation | Q39589692 | ||
| Increased neutralizing antibody response after simultaneous immunization with leucogen and the feline leukemia virus transmembrane protein. | Q39839274 | ||
| Mutational analysis of the cysteine residues in the hepatitis B virus small envelope protein. | Q40046380 | ||
| Hepadnavirus infection requires interaction between the viral pre-S domain and a specific hepatocellular receptor. | Q40048570 | ||
| Production of virus-like particles for vaccines | Q40094178 | ||
| Biochemical and immunological characterization of the duck hepatitis B virus envelope proteins | Q40281152 | ||
| Immunization of flavivirus West Nile recombinant envelope domain III protein induced specific immune response and protection against West Nile virus infection. | Q40457381 | ||
| Purification of hepatitis B surface antigen virus-like particles from recombinant Pichia pastoris and in vivo analysis of their immunogenic properties | Q42261166 | ||
| Neutralizing monoclonal antibodies to bovine viral diarrhoea virus bind to the 56K to 58K glycoprotein | Q42988910 | ||
| Immunogens of bovine viral diarrhea virus | Q43035483 | ||
| Isolation and properties of genetically defined strains of the methylotrophic yeast Hansenula polymorpha CBS4732. | Q43864273 | ||
| Vaccine manufacturing: challenges and solutions | Q44862237 | ||
| Immunization with the transmembrane protein of a retrovirus, feline leukemia virus: absence of antigenemia following challenge | Q45371002 | ||
| Antibodies neutralizing feline leukaemia virus (FeLV) in cats immunized with the transmembrane envelope protein p15E. | Q45420692 | ||
| Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine | Q48004555 | ||
| Human hepatitis B vaccine from recombinant yeast | Q52850114 | ||
| Virus-like particles: Next-generation nanoparticles for targeted therapeutic delivery. | Q54290026 | ||
| Simultaneous expression of the S and L surface antigens of hepatitis B, and formation of mixed particles in the methylotrophic yeast, Hansenula polymorpha | Q67980541 | ||
| Improved determination of total serum lipids by the sulfo-phospho-vanillin reaction | Q70403772 | ||
| Highly-efficient electrotransformation of the yeast Hansenula polymorpha | Q72178965 | ||
| Hepatitis B surface antigen (HBsAg) derived from yeast cells (Hansenula polymorpha) used to establish an influence of antigenic subtype (adw2, adr, ayw3) in measuring the immune response after vaccination | Q74092600 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 1 | |
| P304 | page(s) | 17 | |
| P577 | publication date | 2018-02-05 | |
| P1433 | published in | Microbial Cell Factories | Q15766995 |
| P1476 | title | Establishment of a yeast-based VLP platform for antigen presentation | |
| P478 | volume | 17 |
| Q64074147 | Advances in Using as Chassis for Recombinant Protein Production |
| Q93099494 | Display of malaria transmission-blocking antigens on chimeric duck hepatitis B virus-derived virus-like particles produced in Hansenula polymorpha |
| Q97526333 | Integrated Process for Capture and Purification of Virus-Like Particles: Enhancing Process Performance by Cross-Flow Filtration |
| Q90024117 | Malaria vaccine candidates displayed on novel virus-like particles are immunogenic and induce transmission-blocking activity |
| Q93079245 | Sneaking Out for Happy Hour: Yeast-Based Approaches to Explore and Modulate Immune Response and Immune Evasion |
| Q89967522 | Synthesis and Assembly of Hepatitis B Virus-Like Particles in a Pichia pastoris Cell-Free System |
| Q89980645 | Yeast display platform technology to prepare oral vaccine against lethal H7N9 virus challenge in mice |
| Q100569264 | vB_EcoS_NBD2 bacteriophage-originated polytubes as a carrier for the presentation of foreign sequences |
Search more.